RxDoctor Payments Data

Erika Cecilia Montecillo, NP

Nurse Practitioner · McAllen, TXNPI 1265804785

Payments from drug & device makers

$702in general payments, 2019–2025

Across 35 payments — averaging $20.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$137
  • Johnson & Johnson$127
  • Astellas Pharma US Inc$106
  • Novo Nordisk$96
  • AbbVie$95
  • Novartis$39
  • plus $102 from 5 others

What the payments were for

  • Food & beverage$61087%
  • Education$9213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$702 in reported general payments places this provider in the 70th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$54,457
Medicare patients
266
Services billed
1,321

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide70$72,724
FarxigaDapagliflozin Propanediol57$55,972
JardianceEmpagliflozin50$48,864
XifaxanRifaximin11$33,864
EliquisApixaban21$28,164
RybelsusSemaglutide17$27,379
TrulicityDulaglutide19$22,896
LinzessLinaclotide24$16,927
RexultiBrexpiprazole12$16,446
MyrbetriqMirabegron21$14,949
NexiumEsomeprazole Magnesium16$12,010
JanuviaSitagliptin Phosphate12$11,476
EntrestoSacubitril/Valsartan13$9,499
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$7,475
Breo ElliptaFluticasone/Vilanterol12$5,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$96$100,10287 claims
AstraZenecaFarxiga, Nexium$26$67,98373 claims
Boehringer IngelheimJardiance$14$48,86450 claims
Lilly USA, LLCTrulicity$137$22,89619 claims
AbbVieLinzess$95$16,92724 claims
Otsuka America Pharmaceutical, Inc.Rexulti$30$16,44612 claims
Astellas Pharma US IncMyrbetriq$106$14,94921 claims
NovartisEntresto$39$9,49913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →